KELOWNA, BC , March 4, 2026 /PRNewswire/ -- Doseology Sciences Inc. (CSE: MOOD) (OTCQB: DOSEF) (FSE: VU70) ("Doseology" or the "Company") today announced the launch of the Feed That Brain® Energy Pouches, marking the Company's first direct-to-consumer pilot program in the United States.

Feed That Brain Energy Pouches deliver clean, controlled energy in a discreet oral pouch format, powered by Doseology®. The nicotine-free, caffeine-based product is designed to provide predictable, portion-controlled stimulation without sugar, smoke, or liquid consumption. The pouches are now available exclusively to U.S. consumers at feedthatbrain.com and Amazon.com.

The U.S. pilot represents a key milestone in Doseology's strategy to validate oral pouch delivery as a scalable stimulant platform, beginning with non-nicotine energy products. The Company will use this phase to evaluate consumer adoption, usage frequency, and repeat purchase behaviour, with particular focus on underserved demographics seeking alternatives to traditional energy drinks.

"This U.S. pilot is a disciplined and deliberate step in Doseology's strategy to build a scalable oral stimulant platform," said Larry Latowsky, Executive Chairman of Doseology, "Feed That Brain demonstrates how controlled, non-nicotine energy delivery can meet evolving consumer preferences while generating the operational insight required for responsible growth."

Feed That Brain Energy Pouches are designed for modern, on-the-go use, offering consumers clarity and control without the volatility commonly associated with liquid energy formats. The product reflects Doseology's broader focus on precision dosing, predictability, and experience-led design.

The Company notes that increasing consumer adoption of oral pouch formats reflects a broader shift toward portable and discreet delivery systems. While Feed That Brain is nicotine-free, the rapid growth of the U.S. nicotine pouch category highlights rising acceptance of pouch-based delivery, supporting the long-term relevance of the format.

The Company also announced that it has granted 140,000 restricted share units ("RSUs") and 210,000 performance share units ("PSUs") to a director of the Company. The RSUs vest in equal monthly increments over 36 months from the date of grant. The PSUs vest upon achievement of defined performance milestones, aligning compensation with long-term value creation.

About Doseology Sciences Inc. (CSE: MOOD | OTCQB: DOSEF | FSE: VU70)

Doseology Sciences Inc. specializes in pouch-based oral stimulant and cognitive support products. The rapidly expanding oral stimulant pouch sector is gaining momentum as consumers seek modern, discreet alternatives to traditional delivery formats. Unlike combustible tobacco or vape products, oral stimulant pouches are smokeless and vapor-free, providing an alternative delivery method without inhalation.

From a market perspective, the oral pouch category is experiencing strong global growth as consumers increasingly prioritize convenience, portability, and format innovation. The pouch sector represents one of the most dynamic and high-growth areas in modern functional consumer products.

For more information:

doseology.com / feedthatbrain.com

On behalf of the Board of Directors, Chris Jackson
CEO, Director
Doseology Sciences Inc.

Investor & Media Contact:
Email:hello@doseology.com 
Phone: 604.908.3095

Forward Looking Statements

This press release contains statements that constitute "forward‐looking information" within the meaning of applicable securities laws. Forward‐looking information is often identified by the words "may," "would," "could," "should," "will," "intend," "plan," "anticipate," "believe," "estimate," "expect" or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company's management's expectations, estimates or projections concerning the business of the Company's future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company's prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. For more information, investors should review the Company's filings which are available on SEDAR+.

No securities regulatory authority has either approved or disapproved of the contents of this press release. 

Logo - https://mma.prnewswire.com/media/2858641/5832014/Doseology_Sciences_Inc_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/doseology-launches-feed-that-brain-oral-stimulant-pouches-in-the-us-through-direct-to-consumer-pilot-302701622.html

SOURCE Doseology Sciences Inc.